Method for detecting hemolysis
View Patent ↗This invention provides a method for determining the presence of hemolyzed erythrocytes in blood by detecting erythrocyte adenylate kinase in a serum sample from the blood. This invention also provides a method for diagnosing a hemolytic condition in a subject suspected to be suffering from hemolysis, as well as a method for monitoring hemolysis in a subject undergoing treatment for a hemolytic condition.
1. A method for diagnosing erythrocyte hemolysis in a subject who is suspected of having erythrocyte hemolysis in vivo, the method consiting essentially of the steps of:
(a) obtaining a serum sample from a subject who is suspected of having erythrocyte hemolysis in vivo; and
(b) determining the level of erythrocyte adenylate kinase activity in said sample, the presence of at least about 20 U/L erythrocyte adenylate kinase activity in said sample being indicative of erythrocyte hemolysis in vivo in said subject.
2. A method for diagnosing erythrocyte hemolysis in a subject who may have erythrocyte hemolysis, the method comprising the steps of:
(a) obtaining a serum sample from the subject; and
(b) determining the level of erythrocyte adenylate kinase activity in the sample by
determining a value for total adenylate kinase activity in the serum sample;
determining a value for percentage erythrocyte adenylate kinase in the sample; and
determining erythrocyte adenylate kinase activity in the sample by multiplying the value for percentage erythrocyte adenylate kinase by the value for total adenylate kinase activity,
the presence of at least about 20 U/L erythrocyte adenylate kinase activity in the sample being indicative of erythrocyte hemolysis in the subject.
3. A method for diagnosing erythrocyte hemolysis in a subject who may have erythrocyte hemolysis, the method comprising the steps of:
(a) obtaining a serum sample from the subject; and
(b) determining the level of erythrocyte adenylate kinase activity in the sample using an antibody that is specific for and binds to erythrocyte adenylate kinase,
the presence of at least about 20 U/L erythrocyte adenylate kinase activity in the sample being indicative of erythrocyte hemolysis in the subject.
4. The method of claim 3 , wherein erythrocyte adenylate kinase-bound antibody is detected using a radioimmunoassay.
5. The method of claim 3 , wherein erythrocyte adenylate kinase-bound antibody is detected using an enzyme-linked immunosorbent assay (ELISA).
6. The method of claim 3 , wherein erythrocyte adenylate kinase-bound antibody is detected using immunoprecipitation.
7. The method of claim 3 , wherein the antibody is labeled with a detectable marker.
8. The method of claim 3 , wherein the antibody is labeled with a radioisotope.
9. The method of claim 3 , wherein the antibody is labeled with radioactive iodine.